{"id":35125,"date":"2026-05-01T17:41:00","date_gmt":"2026-05-01T12:11:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35125"},"modified":"2026-05-01T15:11:58","modified_gmt":"2026-05-01T09:41:58","slug":"aacr-2026-highlights","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights","title":{"rendered":"AACR 2026: A Deep Dive into Cancer\u2019s Next Frontier \u2013 Key Abstracts &amp; Insights"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f5d8c053da0\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f5d8c053da0\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#Quick_Highlights_of_AACR_2026\" >Quick Highlights of AACR 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#Strategic_Takeaways_for_Industry_Leaders\" >Strategic Takeaways for Industry Leaders<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#Novel_Therapy_Classes_with_preclinical_and_Early-Stage_Data\" >Novel Therapy Classes with preclinical and Early-Stage Data<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#D3_Bios_multi-layered_strategy_targeting_both_validated_G12C_and_emerging_G12D_MAPK_pathways\" >D3 Bio\u2019s multi-layered strategy targeting both validated (G12C) and emerging (G12D, MAPK) pathways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#CStones_pipeline_advancement_into_next-generation_ADCs\" >CStone\u2019s pipeline advancement into next-generation ADCs<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#Antengene_Highlighting_Next-Generation_ADC_and_AnTenGager_T-cell_engager_TCE\" >Antengene Highlighting Next-Generation ADC and AnTenGager T-cell engager (TCE)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#Verismo_Therapeutics_presented_clinical_data_for_its_multi-chain_KIR-CAR_platform_SynKIR-110\" >Verismo Therapeutics presented clinical data for its multi-chain KIR-CAR platform (SynKIR-110)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#KRASRASON_Inhibitors_Next-generation_targeted_therapy\" >KRAS\/RAS(ON) Inhibitors (Next-generation targeted therapy):<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\/#Oncology_Expert_Perspectives_and_Insights\" >Oncology Expert Perspectives and Insights<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>The American Association for Cancer Research (AACR) is the world&#8217;s oldest and largest professional association related to cancer research. The AACR Annual Meeting 2026 is one of the most prominent global oncology conferences, showcasing cutting-edge advances across cancer biology, translational research, and early clinical development. It serves as a key platform for unveiling early-stage (preclinical to Phase II) data, novel mechanisms, and biomarker-driven therapies, often shaping future oncology pipelines and partnerships.<\/p>\n\n\n\n<p><strong>When &amp; Where: <\/strong>April 17\u201322, 2026 | San Diego, USA<\/p>\n\n\n\n<p><strong>Theme:<\/strong> Precision; Partnership; Purpose; Advancing Cancer Science to Save Lives Globally.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-quick-highlights-of-aacr-2026\"><span class=\"ez-toc-section\" id=\"Quick_Highlights_of_AACR_2026\"><\/span><strong>Quick Highlights of AACR 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The AACR Annual Meeting 2026 reinforced its position as a leading platform for showcasing early-stage oncology innovation, translational science, and next-generation therapeutic strategies across tumor biology, precision medicine, and clinical development. The strongest attention was directed toward next-generation KRAS\/RAS (ON) inhibitors, <a href=\"https:\/\/www.delveinsight.com\/report-store\/antibody-drug-conjugate-market\">ADCs<\/a>, T-cell engagers, CAR-T, and gene therapies, with important readouts across solid tumors and hematologic malignancies, particularly in NSCLC, ovarian cancer, breast cancer, colorectal cancer, and myeloma.<\/p>\n\n\n\n<p>Lung cancer (especially KRAS-driven NSCLC) remained the dominant indication, followed by breast cancer, ovarian cancer, and AML, reflecting areas of high unmet need and commercial opportunity.<\/p>\n\n\n\n<p>Several companies stood out at the meeting, including <strong>Greenwich Life Sciences, BriaCell, Calidi, Revolution Medicines, D3 Bio, SELLAS Life Sciences, CStone, Whitehawk Therapeutics, Antengene, HUTCHMED, IDEAYA, Jazz Pharmaceuticals, Genprex, and OBI Pharma<\/strong>. Their programs spanned recurrence-prevention immunotherapy, late-line breast cancer immunotherapy, tumor-localized virotherapy, next-wave ADCs and T-cell engagers, lung cancer gene therapy, and multi-platform biologics, highlighting the breadth and strategic relevance of the AACR 2026 pipeline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-takeaways-for-industry-leaders\"><span class=\"ez-toc-section\" id=\"Strategic_Takeaways_for_Industry_Leaders\"><\/span><strong>Strategic Takeaways for Industry Leaders<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AACR 2026 signals that <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\">KRAS-targeted therapy<\/a> is transitioning into a long-term franchise opportunity, similar to EGFR or HER2, with multiple lines of therapy and lifecycle expansion potential. AACR 2026 highlights a clear paradigm shift in oncology innovation:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>KRAS\/RAS biology is now commercially actionable\u00a0<\/li>\n\n\n\n<li>ADCs and cell therapies are evolving into multi-platform ecosystems\u00a0<\/li>\n\n\n\n<li>Precision diagnostics are becoming integral to drug development\u00a0<\/li>\n\n\n\n<li>Early-stage data is increasingly predictive of regulatory acceleration\u00a0<\/li>\n\n\n\n<li>Following Phase I AACR 2026 data, the lunresertib + zedoresertib combination received FDA Fast Track designation for genomically defined platinum-resistant ovarian cancer, supporting accelerated development in a high unmet-need setting<\/li>\n<\/ul>\n\n\n\n<p><strong>For Pharma stakeholders, investment focus should align with:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>First-in-class biology (KRAS G12D, pan-RAS)\u00a0<\/li>\n\n\n\n<li>Platform scalability (ADCs, cell therapy)\u00a0<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-novel-therapy-classes-with-preclinical-and-early-stage-data\"><span class=\"ez-toc-section\" id=\"Novel_Therapy_Classes_with_preclinical_and_Early-Stage_Data\"><\/span><strong>Novel Therapy Classes with preclinical and Early-Stage Data<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>AACR 2026 spotlighted a strong shift toward first-in-class and next-generation modalities, with a clear concentration in early-stage (preclinical and Phase I) development. Among these, KRAS-targeted therapies emerged as one of the most prominent and closely watched areas. Early-stage (preclinical\/Phase I) abstracts are captured below in the table.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td colspan=\"6\"><strong>Early-Stage Novel Oncology Therapies Highlighted at AACR 2026<\/strong><\/td><\/tr><tr><td><strong>Drug Name<\/strong><\/td><td><strong>Target<\/strong><\/td><td><strong>Indication<\/strong><\/td><td><strong>Clinical Stage<\/strong><\/td><td><strong>Data&nbsp;<\/strong><\/td><td><strong>Company<\/strong><\/td><\/tr><tr><td><strong>Elisrasib (D3S-001)<\/strong><\/td><td>KRAS G12C inhibitor<\/td><td>NSCLC previously treated with\/without KRAS G12C inhibitor; previously treated metastatic CRC and PDAC<\/td><td>Phase I\/II<\/td><td>Elisrasib demonstrated robust and durable responses, achieving high disease control rates of 98.5% in KRAS G12C inhibitor\u2013na\u00efve patients and 83.9% in refractory patients.<\/td><td rowspan=\"3\">D3 Bio<\/td><\/tr><tr><td><strong>D3S-002<\/strong><\/td><td>ERK1\/2 inhibitor<\/td><td>Advanced solid tumors with MAPK pathway mutations<\/td><td>Phase I<\/td><td>D3S-002 demonstrates predictable, dose-proportional PK consistent with its preclinically designed pulsatile exposure profile, supporting its development as an optimal ERKi partner for synergistic combination with other MAPK pathway-targeted therapies.<\/td><\/tr><tr><td><strong>D3S-003<\/strong><\/td><td>KRAS G12D inhibitor<\/td><td>Solid tumor<\/td><td>Preclinical<\/td><td>Predicted human PK supports once-daily dosing feasibility. The model suggests favorable oral bioavailability and dose-dependent exposure.<\/td><\/tr><tr><td><strong>SynKIR-110 KIR-CAR<\/strong><\/td><td>Autologous T cells Transduced with Mesothelin KIR-CAR<\/td><td>Advanced solid tumors, including ovarian cancer, mesothelioma, and cholangiocarcinoma<\/td><td>Preclinical<\/td><td>Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches.<\/td><td>Verismo Therapeutics<\/td><\/tr><tr><td><strong>FP012<\/strong><\/td><td>TL1A x IL10MM fusion protein<\/td><td>Inflammatory bowel disease and other inflammatory indications<\/td><td>Preclinical(IND-enabling CMC\/GLP toxicology planned in 2026)<\/td><td>Fapon Biopharma showcased its core platforms\u2014IL-10\u2013biased engineering, antibody fusion, and VHH-based T-cell engagers\u2014demonstrating its focus on advancing next-generation therapies in immuno-oncology and autoimmune diseases.<\/td><td>Fapon Biotech<\/td><\/tr><tr><td><strong>ATG-125<\/strong><\/td><td>B7 H3 x PD-L1 bispecific antibody-drug conjugate<\/td><td rowspan=\"2\">Solid tumors<\/td><td>Preclinical<\/td><td>ATG-125 demonstrated synergistic IO+ADC antitumor activity via enhanced internalization and potential immune restoration, supporting further development in solid tumors.<\/td><td rowspan=\"2\">Antengene<\/td><\/tr><tr><td><strong>ATG-106<\/strong><\/td><td>CDH6 x CD3 TCE<\/td><td>Preclinical<\/td><td>ATG-106 showed limited T-cell binding without target cells, potent tumor cytotoxicity, and encouraging in vivo efficacy in ovarian and kidney models, with favorable non-human primate safety supporting its continued development as a CDH6-targeted TCE.<\/td><\/tr><tr><td><strong>Zoldonrasib<\/strong><\/td><td>RAS(ON) G12D-selective inhibitor<\/td><td>Previously treated KRAS G12D NSCLC<\/td><td>Phase I<\/td><td>Zoldonrasib\u2019s 52% objective response rate in 27 patients with previously treated NSCLC, with an average progression-free survival of 11.1 months.<\/td><td>Revolution Medicines<\/td><\/tr><tr><td><strong>ZW418<\/strong><\/td><td>PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload<\/td><td>NSCLC<\/td><td>Preclinical<\/td><td>Strong anti-tumor activity observed across PTK7-expressing RAS-mutant NSCLC xenograft models, at doses as low as 1 mg\/kg.Favorable pharmacokinetics and tolerability support further development.<\/td><td>Zymeworks<\/td><\/tr><tr><td><strong>Lunresertib + Zedoresertib<\/strong><\/td><td>PKMYT1 inhibitor + Wee1 inhibitor<\/td><td>Genomic-defined platinum-resistant ovarian cancer<\/td><td>Phase I<\/td><td>Demonstrated promising antitumor activity in Phase I (MYTHIC trial) across advanced solid tumors.Achieved ~50% overall response rate (ORR), increasing to ~60% in CCNE1-amplified ovarian cancer.Disease control rate ~68.5%, with broad tumor shrinkage observedShowed durable responses and a manageable safety profile.<\/td><td>Debiopharm<\/td><\/tr><tr><td><strong>Denikitug<\/strong><\/td><td>CCR8 monoclonal antibody<\/td><td>Solid tumors<\/td><td>Phase I<\/td><td>Efficacy: ORR of 8% and DCR of 46% in 52 evaluable patientsSafety: No Grade 4\/5 TRAEs; most common AEs were pruritic and maculopapular rash.<\/td><td>Gilead<\/td><\/tr><tr><td><strong>REQORSA Gene Therapy (quaratusugene ozeplasmid)<\/strong><\/td><td>Non-viral gene therapy that delivers thetumor suppressor gene to cancer cells<\/td><td>Lung cancer(NSCLC)<\/td><td>Preclinical<\/td><td>Reqorsa induced apoptosis and decreased tumor volume in alk-eml4 positive translocated NSCLC Cell Lines and in Vivo Mouse Studies. REQORSA Boosts Natural Killer (NK) Cell Antitumor Activity.<\/td><td>Genprex<\/td><\/tr><tr><td><strong>Nuzefatide pevedotin + nivolumab<\/strong><\/td><td>EphA2 toxin conjugate<\/td><td>Solid tumors(previously treated metastatic urothelial cancer)<\/td><td>Phase I\/II<\/td><td>Efficacy: 40% confirmed ORR in EphA2+ tumors; 100% ORR in MMAE-na\u00efve EphA2+ patientsSafety: Nuzefatide + nivolumab was well tolerated, with no \u2265Grade 3 TRAEs of concern or hemorrhagic events.<\/td><td>Bicycle Therapeutics<\/td><\/tr><tr><td><strong>SGR-3515<\/strong><\/td><td>Wee1\/Myt1 inhibitor<\/td><td>Solid tumors<\/td><td>Phase I<\/td><td>Efficacy: Preliminary anti-tumor activity with 64.7% disease control rate at \u2265100 mg (ovarian, breast, uterine cancers).Safety: Generally well tolerated with intermittent dosing (3 days on\/11 days off).<\/td><td>Schr\u00f6dinger<\/td><\/tr><tr><td><strong>HMPL-A580<\/strong><\/td><td>PI3K\/PIKK-EGFR Antibody-Targeted Therapy Conjugate (ATTC)<\/td><td>Solid tumors<\/td><td>Preclinical<\/td><td>Demonstrated potent and selective anti-tumor activity in EGFR-expressing tumor models.Showed targeted delivery of a PI3K\/PIKK inhibitor payload, improving tumor specificity.<\/td><td>Hutchmed<\/td><\/tr><tr><td><strong>CS5007<\/strong><strong>CS5006<\/strong><strong>CS5008<\/strong><\/td><td>Bispecific ADC (EGFR\/HER3);ITGB4-Targeting ADC;DLL3\/SSTR2 Bispecific ADC<\/td><td>Advanced solid tumors (NSCLC, ESCC, HNSCC, CRC, pancreatic, and breast cancer)<\/td><td>Preclinical<\/td><td>CS5007: Demonstrated a superior pharmacokinetics (PK)\/ Pharmacodynamics (PD) profile compared to BL-B01D1 in the FaDu CDX model.CS5006: Showed broad anti-tumor efficacy across multiple solid tumor modelsCS5008: Showed strong internalization, high stability, and long half-life (~14 days).<\/td><td>CStone Pharmaceuticals<\/td><\/tr><tr><td><strong>CLD-401<\/strong><\/td><td>Target TROP2, a cell-surface glycoprotein<\/td><td>NSCLC, head and neck cancer, and other tumor types<\/td><td>Preclinical&nbsp;<\/td><td>CLD-401 data at AACR 2026 demonstrated strong TME-driven immune activation (NK\/NK-T\/\u03b3\u03b4 T cells) via tumor-localized IL-15 expression, leading to robust preclinical anti-tumor activity.<\/td><td>Calidi Biotherapeutics<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><em>\u201cFollowing Phase I data presentation at AACR 2026 (MYTHIC trial), Debiopharm received FDA Fast Track designation for the combination of lunresertib (PKMYT1 inhibitor) and zedoresertib (WEE1 inhibitor). The designation targets genomically defined, platinum-resistant ovarian cancer (e.g., CCNE1 amplification, FBXW7\/PPP2R1A mutations). The Fast Track status aims to accelerate development and regulatory review, reflecting strong potential in a high unmet-need setting.\u201d<\/em><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-d3-bio-s-multi-layered-strategy-targeting-both-validated-g12c-and-emerging-g12d-mapk-pathways\"><span class=\"ez-toc-section\" id=\"D3_Bios_multi-layered_strategy_targeting_both_validated_G12C_and_emerging_G12D_MAPK_pathways\"><\/span><strong>D3 Bio\u2019s multi-layered strategy targeting both validated (G12C) and emerging (G12D, MAPK) pathways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>D3 Bio highlighted a KRAS-focused pipeline across major solid tumors, led by Elisrasib (D3S-001), a <a href=\"https:\/\/www.delveinsight.com\/blog\/kras-inhibitors-beyond-g12c\">next-generation KRAS G12C inhibitor<\/a> in NSCLC, CRC, and PDAC. Clinical data show deeper and more durable responses, including in patients resistant to earlier therapies, underscoring its potential to improve outcomes in KRAS G12C\u2013mutant NSCLC. Currently, sotorasib (LUMAKRAS) and adagrasib (KRAZATI) are approved for this population.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cstone-s-pipeline-advancement-into-next-generation-adcs\"><span class=\"ez-toc-section\" id=\"CStones_pipeline_advancement_into_next-generation_ADCs\"><\/span><strong>CStone\u2019s pipeline advancement into next-generation ADCs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The Company presented promising preclinical data for three of its novel or differentiated antibodies. If translated into clinical success, these assets could substantially increase CStone\u2019s addressable market and revenue potential, making this news potentially price-sensitive and impactful for share value. ADCs, <strong>CS5007<\/strong> (EGFR\/HER3), <strong>CS5006 <\/strong>(ITGB4), and <strong>CS5008 <\/strong>(DLL3\/SSTR2).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-antengene-highlighting-next-generation-adc-and-antengager-t-cell-engager-tce\"><span class=\"ez-toc-section\" id=\"Antengene_Highlighting_Next-Generation_ADC_and_AnTenGager_T-cell_engager_TCE\"><\/span><strong>Antengene Highlighting Next-Generation ADC and AnTenGager T-cell engager (TCE)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Antengene demonstrated strong momentum in the bispecific and TCE space with <strong>ATG-125, ATG-106, and ATG-112<\/strong>. Leveraging its AnTenGager platform, the company aims to mitigate cytokine release syndrome (CRS) while enabling targeting of low-antigen\u2013expressing tumors, including ovarian and renal cancers. These preclinical findings position Antengene at the forefront of expanding TCEs beyond hematologic malignancies into solid tumors, highlighting early-stage yet high-potential immunotherapy assets.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-verismo-therapeutics-presented-clinical-data-for-its-multi-chain-kir-car-platform-synkir-110\"><span class=\"ez-toc-section\" id=\"Verismo_Therapeutics_presented_clinical_data_for_its_multi-chain_KIR-CAR_platform_SynKIR-110\"><\/span><strong>Verismo Therapeutics presented clinical data for its multi-chain KIR-CAR platform (SynKIR-110)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Verismo Therapeutics presented late-breaking Phase I data on <strong>KIR-CAR therapy SynKIR-110<\/strong>, demonstrating early clinical activity and strong safety in mesothelin-expressing solid tumors, marking a significant step toward expanding <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-market-forecast\">CAR-T therapies<\/a> beyond hematologic malignancies into solid tumors.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-kras-ras-on-inhibitors-next-generation-targeted-therapy\"><span class=\"ez-toc-section\" id=\"KRASRASON_Inhibitors_Next-generation_targeted_therapy\"><\/span><strong>KRAS\/RAS(ON) Inhibitors (Next-generation targeted therapy):<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The KRAS\/RAS pathway emerged as one of the most strategically important themes at AACR 2026, reflecting a transition from \u201cundruggable\u201d biology to a highly competitive and differentiated therapeutic landscape.<\/p>\n\n\n\n<p><strong>Zoldonrasib (RMC-9805):<\/strong> Revolution Medicines presented Phase I data of oral RAS (ON) G12D-selective inhibitor in patients with previously treated KRAS NSCLC. Early Phase I data showed encouraging anti-tumor activity in <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\">NSCLC<\/a>. The emerging profile supports advancing zoldonrasib across monotherapy and combination settings in lung cancer and other RAS G12D-driven cancers.<\/p>\n\n\n\n<p><strong>Daraxonrasib:<\/strong> Revolution Medicines is riding high on pivotal data with its pan-RAS inhibitor daraxonrasib, but its KRAS G12D-selective inhibitor zoldonrasib also continues to look good. Revolution Medicines Moves beyond mutation-specific targeting. Potential to become a backbone therapy across multiple cancers. <strong>Revolution Medicines\u2019 Daraxonrasib<\/strong> Nearly Doubles Survival in KRAS-Mutant Pancreatic Cancer.<\/p>\n\n\n\n<p><strong>BlossomHill Therapeutics<\/strong> presented new preclinical data supporting the continued advancement of its clinical programs, BH-30643, a first-in-class, mutant-selective, macrocyclic OMNI-EGFRTM inhibitor, and BH-30236, an oral CLK inhibitor for hematologic malignancies. BH-501284, a non-covalent, pan-KRAS inhibitor for the treatment of diverse KRAS-mutant tumors.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td colspan=\"4\"><strong>Next-Generation KRAS Therapies: Clinical Landscape<\/strong><\/td><\/tr><tr><td><strong>Therapy<\/strong><\/td><td><strong>Target<\/strong><\/td><td><strong>Stage<\/strong><\/td><td><strong>Key Advantage<\/strong><\/td><\/tr><tr><td><strong>Zoldonrasib<\/strong><\/td><td>KRAS G12D-specific NSCLC<\/td><td>Early clinical<\/td><td>First mover in G12D<\/td><\/tr><tr><td><strong>Elisrasib<\/strong><\/td><td>KRAS G12C next-gen<\/td><td>Early clinical<\/td><td>Overcomes resistance<\/td><\/tr><tr><td><strong>Daraxonrasib<\/strong><\/td><td>Pan-RAS (ON-state) metastatic pancreatic adenocarcinoma<\/td><td>Clinical<\/td><td>Broad tumor coverage<\/td><\/tr><tr><td><strong>Elironrasib<\/strong><\/td><td>G12C resistance<\/td><td>Early clinical<\/td><td>Lifecycle extension<\/td><\/tr><tr><td><strong>BH-501284<\/strong><\/td><td>Diverse KRAS-mutant tumors<\/td><td>Preclinical<\/td><td>Wide applicability<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-oncology-expert-perspectives-and-insights\"><span class=\"ez-toc-section\" id=\"Oncology_Expert_Perspectives_and_Insights\"><\/span><strong>Oncology Expert Perspectives and Insights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Experts from across oncology specialties highlight research being presented at the 2026 AACR Annual Meeting.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The researchers focused on the RNA-modifying enzyme NAT10 and its interaction with the oncogene MYC. They found that elevated NAT10 activity promoted immune evasion by enhancing autophagy-mediated loss of MHC class I molecules, which are essential for immune cells to recognize and target cancer.<\/li>\n\n\n\n<li>The researchers say the AI model is especially useful in situations where data are scarce, such as rare patient immune types or newly identified cancer targets. The approach could help speed the development of personalized cancer vaccines and immune-based treatments.<\/li>\n\n\n\n<li>One of the biggest challenges in immunotherapy is determining which peptides are actually presented by MHC molecules and can be recognized by T cells. By combining AlphaFold 3 structural predictions with a geometry-aware learning framework, our approach captures the physical interactions underlying peptide\u2013MHC binding, allowing us to identify promising epitopes with higher accuracy even in low-data settings.<\/li>\n\n\n\n<li>Researchers discovered a metabolic vulnerability in <a href=\"https:\/\/www.delveinsight.com\/report-store\/acute-myeloid-leukemia-aml-market\">Acute Myeloid Leukemia (AML)<\/a>. Leukemia cells depend on the protein eIF4A1 to generate the nutrients they need for rapid growth. By blocking this protein in preclinical models, scientists were able to disrupt the cancer&#8217;s energy supply, slowing disease progression and extending survival when combined with other metabolic-targeted drugs.<\/li>\n<\/ul>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-inhibitors-market\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/KRAS-Inhibitors-Market-Assessment-1024x194.webp\" alt=\"KRAS Inhibitors Market Assessment\" class=\"wp-image-35129\" srcset=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/KRAS-Inhibitors-Market-Assessment-1024x194.webp 1024w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/KRAS-Inhibitors-Market-Assessment-300x57.webp 300w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/KRAS-Inhibitors-Market-Assessment-150x28.webp 150w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/KRAS-Inhibitors-Market-Assessment-768x145.webp 768w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/KRAS-Inhibitors-Market-Assessment-1536x291.webp 1536w, https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/KRAS-Inhibitors-Market-Assessment.webp 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>The American Association for Cancer Research (AACR) is the world&#8217;s oldest and largest professional association related to cancer research. The AACR Annual Meeting 2026 is one of the most prominent global oncology conferences, showcasing cutting-edge advances across cancer biology, translational research, and early clinical development. It serves as a key platform for unveiling early-stage (preclinical [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35127,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[3057,22965,20587,17026,21632],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-35125","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-aacr","tag-aacr-2026","tag-aacr-conference","tag-kras-inhibitors","tag-kras-inhibitors-market","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Top Breakthroughs from AACR 2026<\/title>\n<meta name=\"description\" content=\"The American Association for Cancer Research (AACR) is the world&#039;s oldest and largest professional association related to cancer research.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Top Breakthroughs from AACR 2026\" \/>\n<meta property=\"og:description\" content=\"The American Association for Cancer Research (AACR) is the world&#039;s oldest and largest professional association related to cancer research.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-01T12:11:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/aacr-2026-highlights.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Top Breakthroughs from AACR 2026","description":"The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights","og_locale":"en_US","og_type":"article","og_title":"Top Breakthroughs from AACR 2026","og_description":"The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research.","og_url":"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-05-01T12:11:00+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/aacr-2026-highlights.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights","url":"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights","name":"Top Breakthroughs from AACR 2026","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/aacr-2026-highlights.webp","datePublished":"2026-05-01T12:11:00+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/aacr-2026-highlights#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/aacr-2026-highlights.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/aacr-2026-highlights.webp","width":466,"height":284,"caption":"aacr-2026-highlights"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/05\/aacr-2026-highlights-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AACR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AACR 2026<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AACR Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS Inhibitors<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">KRAS inhibitors market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AACR<\/span>","<span class=\"advgb-post-tax-term\">AACR 2026<\/span>","<span class=\"advgb-post-tax-term\">AACR Conference<\/span>","<span class=\"advgb-post-tax-term\">KRAS Inhibitors<\/span>","<span class=\"advgb-post-tax-term\">KRAS inhibitors market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 17 hours ago","modified":"Updated 20 hours ago"},"absolute_dates":{"created":"Posted on May 1, 2026","modified":"Updated on May 1, 2026"},"absolute_dates_time":{"created":"Posted on May 1, 2026 5:41 pm","modified":"Updated on May 1, 2026 3:11 pm"},"featured_img_caption":"aacr-2026-highlights","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35125"}],"version-history":[{"count":3,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35125\/revisions"}],"predecessor-version":[{"id":35131,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35125\/revisions\/35131"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35127"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35125"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35125"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}